Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Brain-first forms of Parkinson’s Disease are over-represented in patients with non-responsive resting tremor

View ORCID ProfileMarcelo D. Mendonça, View ORCID ProfilePedro Ferreira, View ORCID ProfileRaquel Barbosa, View ORCID ProfileJoaquim Alves da Silva
doi: https://doi.org/10.1101/2024.07.23.24310859
Marcelo D. Mendonça
1Champalimaud Research and Clinical Centre, Champalimaud Foundation, Av. Brasília, 1400-038, Lisboa, Portugal
2NOVA Medical School, NMS, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria 130, 1169-056, Lisboa, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcelo D. Mendonça
  • For correspondence: marcelo.mendonca{at}neuro.fchampalimaud.org joaquim.silva{at}neuro.fchampalimaud.org
Pedro Ferreira
1Champalimaud Research and Clinical Centre, Champalimaud Foundation, Av. Brasília, 1400-038, Lisboa, Portugal
3NOVA School of Science and Technology, FCT NOVA, Universidade NOVA de Lisboa, Largo da Torre, 2829-516, Caparica, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pedro Ferreira
Raquel Barbosa
4Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d’Investigation Clinique CIC1436, NeuroToul COEN Center, Toulouse, NS-PARK/FCRIN Network, University Hospital of Toulouse, allée Jean Dausset, 31300, Toulouse, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raquel Barbosa
Joaquim Alves da Silva
1Champalimaud Research and Clinical Centre, Champalimaud Foundation, Av. Brasília, 1400-038, Lisboa, Portugal
2NOVA Medical School, NMS, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria 130, 1169-056, Lisboa, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joaquim Alves da Silva
  • For correspondence: marcelo.mendonca{at}neuro.fchampalimaud.org joaquim.silva{at}neuro.fchampalimaud.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Motor subtypes in Parkinson’s Disease (PD) are unstable over time, limiting mechanistic insights and biomarker discovery. We focused on Rest Tremor (RT) as a symptom to test for phenotype stability and link them to specific circuits and disease mechanisms. Using the PPMI cohort data over 5 years we found that RT we found that RT is more stable than common Tremor-Dominant definitions, a stability also seen for therapy response. At time of diagnosis, the population of therapy-resistant RT patients was enriched with a brain-first PD profile as predicted by a-Synuclein origin site and connectome (SOC) model. Resistant-RT patients have lower gastrointestinal and cardiovascular symptoms, lower prevalence of probable REM-Sleep behavior disorder, and higher dopaminergic asymmetry compared to therapy-responsive or no tremor patients. Treating RT as a distinct phenomenon revealed a relative phenotypic stability with treatment response being linked to different patterns of disease progression.

Competing Interest Statement

Marcelo Mendonca has received, payment, honoraria or other support from Medtronic, Bial, Pharacademy, Evidenze, AbbVie and Stada. RB has received, payment, honoraria or other support from Medtronic and AbbVie. Other authors report no conflict of interest.

Funding Statement

MM and JAS were supported by grant EurDyscover EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease (EJPRD/0001/2019). MM is supported by the Michael J. Fox Foundation (MJFF-023180) and European Union’s Horizon Programme (Agreement: 101137378, PsyPal project). JAS was supported by the Portuguese Foundation for Technology and Science (FCT) CEEC grant (2020.03118.CEECIND). PF was supported by the Portuguese Foundation for Science and Technology (FCT) through a PhD scholarship (2023.03390.BD) and by the European Union’s Horizon 2020 Research and Innovation Programme through grant H2020-SC1-DTH-2019-875358 (FAITH project).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used ONLY openly available human data. Data used in the preparation of this article were obtained on May, 13, 2023 from the Parkinson’s Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/accessdata-specimens/download-data), RRID:SCR_006431. This analysis used data openly available from PPMI. For up-to-date information on the study, visit http://www.ppmi-info.org. PPMI a public-private partnership is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson’s, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Financial Disclosure/Conflict of Interest: Marcelo Mendonça has received, payment, honoraria or other support from Medtronic, Bial, Pharacademy, Evidenze, AbbVie and Stada. RB has received, payment, honoraria or other support from Medtronic and AbbVie. Other authors report no conflict of interest.

  • Funding sources: MM and JAS were supported by grant EurDyscover – EJPRD19-135, funded by FCT/MCTES through the European Joint Programme for Rare Disease (EJPRD/0001/2019). MM is supported by the Michael J. Fox Foundation (MJFF-023180) and European Union’s Horizon Programme (Agreement: 101137378, PsyPal project). JAS was supported by the Portuguese Foundation for Technology and Science (FCT) CEEC grant (2020.03118.CEECIND). PF was supported by the Portuguese Foundation for Science and Technology (FCT) through a PhD scholarship (2023.03390.BD) and by the European Union’s Horizon 2020 Research and Innovation Programme through grant H2020-SC1-DTH-2019-875358 (FAITH project).

Data Availability

The PPMI data is part of an open database. Access to PPMI data can be requested at https://www.ppmi-info.org/access-data-specimens/download-data.

https://www.ppmi-info.org/access-data-specimens/download-data

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 24, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Brain-first forms of Parkinson’s Disease are over-represented in patients with non-responsive resting tremor
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Brain-first forms of Parkinson’s Disease are over-represented in patients with non-responsive resting tremor
Marcelo D. Mendonça, Pedro Ferreira, Raquel Barbosa, Joaquim Alves da Silva
medRxiv 2024.07.23.24310859; doi: https://doi.org/10.1101/2024.07.23.24310859
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Brain-first forms of Parkinson’s Disease are over-represented in patients with non-responsive resting tremor
Marcelo D. Mendonça, Pedro Ferreira, Raquel Barbosa, Joaquim Alves da Silva
medRxiv 2024.07.23.24310859; doi: https://doi.org/10.1101/2024.07.23.24310859

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)